Literature DB >> 16494639

Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice.

L Boulanger1, J Kim, M Friedman, O Hauch, T Foster, J Menzin.   

Abstract

We conducted a retrospective cohort study of thromboprophylaxis rates and the quality of anticoagulation control among patients with atrial fibrillation (AF) using a large, geographically diverse database of electronic medical records. The study population consisted of 13,709 AF patients treated in US outpatient physician practices. Approximately two-thirds were prescribed warfarin alone or in combination with another drug. Older patients, males, and those with congestive heart failure (CHF) or prior stroke were more likely to receive antithrombotic therapy. Among 6454 patients treated with warfarin who had at least two valid prothrombin time/international normalised ratio test results, approximately half of study days were spent in target range. Female sex, CHF and residence in the Northeast were associated with more time out of range. Our study confirms that, in routine medical practice, warfarin is not prescribed for substantial numbers of eligible patients, and anticoagulation control with warfarin is suboptimal for many of those at risk for thromboembolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16494639     DOI: 10.1111/j.1368-5031.2006.00790.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  22 in total

1.  Warfarin: almost 60 years old and still causing problems.

Authors:  Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335

2.  Dabigatran in atrial fibrillation: pharmacology and clinical trials.

Authors:  Michael D Ezekowitz; Rangadham Nagarakanti
Journal:  J Interv Card Electrophysiol       Date:  2011-06-30       Impact factor: 1.900

3.  Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.

Authors:  Patricia A Cowper; Shubin Sheng; Renato D Lopes; Kevin J Anstrom; Judith A Stafford; Linda Davidson-Ray; Sana M Al-Khatib; Jack Ansell; Paul Dorian; Steen Husted; John J V McMurray; P Gabriel Steg; John H Alexander; Lars Wallentin; Christopher B Granger; Daniel B Mark
Journal:  JAMA Cardiol       Date:  2017-05-01       Impact factor: 14.676

4.  Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.

Authors:  Andrej Janzic; Mitja Kos
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

5.  Erratum: utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillation.

Authors:  Kate Fitch; Jonah Broulette; Bruce Pyenson; Kosuke Iwasaki; Winghan Jacqueline Kwong
Journal:  Am Health Drug Benefits       Date:  2012-05

6.  Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Assessment of Agreement Between Clinicians' Decision and CHA2DS2-VASc and HAS-BLED Scores.

Authors:  Marzieh Balaghi-Inalou; Saeed Alipour Parsa; Latif Gachkar; Sasan Andalib
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-10-26

Review 7.  Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.

Authors:  Jean-Pierre Bassand
Journal:  Europace       Date:  2012-03       Impact factor: 5.214

8.  Costs and clinical consequences of suboptimal atrial fibrillation management.

Authors:  Steven N Singh
Journal:  Clinicoecon Outcomes Res       Date:  2012-03-26

9.  Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial Fibrillation.

Authors:  Catherine J Mercaldi; Kimberly Siu; Stephen D Sander; David R Walker; You Wu; Qian Li; Ning Wu
Journal:  Cardiol Res Pract       Date:  2012-10-02       Impact factor: 1.866

10.  Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices.

Authors:  Edward Ewen; Zugui Zhang; Teresa A Simon; Paul Kolm; Xianchen Liu; William S Weintraub
Journal:  Vasc Health Risk Manag       Date:  2012-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.